TC Medical(SH:600763) Sou Hu Cai Jing·2025-11-04 11:38Core Viewpoint - Tongce Medical (600763) experienced a decline of 1.27% in stock price, closing at 42.76 yuan on November 4, 2025, with significant net outflow of main funds [1][2] Financial Performance - For the first three quarters of 2025, Tongce Medical reported a main revenue of 2.29 billion yuan, a year-on-year increase of 2.56% [3] - The net profit attributable to shareholders was 514 million yuan, up 3.16% year-on-year, while the net profit after deducting non-recurring gains and losses was 509 million yuan, also up 3.09% [3] - In Q3 2025, the company achieved a single-quarter main revenue of 842 million yuan, reflecting a year-on-year increase of 2.34% [3] - The company's gross profit margin stood at 41.69%, with a net profit margin of 26.91% [3] Market Position - Tongce Medical's total market capitalization is 19.126 billion yuan, ranking 8th in the medical services industry [3] - The company has a price-to-earnings ratio (P/E) of 27.93, significantly lower than the industry average of 378.96, indicating a favorable valuation [3] - The return on equity (ROE) is 11.8%, placing it 5th in the industry [3] Fund Flow Analysis - On November 4, 2025, the main funds saw a net outflow of 24.91 million yuan, accounting for 12.73% of the total transaction amount [1][2] - Retail investors contributed a net inflow of 19.62 million yuan, representing 10.03% of the total transaction amount [1][2] - Over the past five days, the stock has seen fluctuating fund flows, with varying levels of net inflow and outflow from main and retail investors [2] Analyst Ratings - In the last 90 days, 10 institutions have rated the stock, with 8 buy ratings and 2 hold ratings, indicating a generally positive outlook [4] - The average target price set by institutions over the past 90 days is 5.201 billion yuan [4]